SCHEDULE 13D/A: Major Shareholder Richard Griffiths Boosts Stake in Silence Therapeutics to 24.4%

Richard Griffiths, a significant shareholder, has increased his beneficial ownership in Silence Therapeutics Plc to 24.4% through recent open market purchases totaling $2.7 million.

Summary

• Richard Ian Griffiths and Ora Capital Limited filed Amendment No. 9 to Schedule 13D for Silence Therapeutics Plc.
• The amendment reflects open market transactions of American Depositary Shares (ADSs) by the Reporting Person and dilution due to an increase in the Issuer's share capital.
• Richard Griffiths beneficially owns an aggregate of 34,543,302 ordinary shares, representing 24.4% of the outstanding ordinary shares.
• Ora Capital Limited beneficially owns 19,221,525 ordinary shares, representing 13.6% of the outstanding ordinary shares.
• Mr. Griffiths purchased 543,581 ADSs in open market transactions between May 8, 2025, and June 24, 2025, for an aggregate price of $2.7 million.
• All purchases were for cash and were funded by companies or personal funds of Mr. Griffiths.
• The percentage ownership is calculated based on 141,690,849 outstanding ordinary shares of Silence Therapeutics Plc, as disclosed in the Issuer's last SEC filing.

Sentiment

Score: 8

Explanation: The significant increase in beneficial ownership by a key insider, Richard Griffiths, through substantial open market purchases, indicates strong confidence in Silence Therapeutics Plc. This insider buying is generally viewed positively by the market.

Positives

• Increased beneficial ownership by a key insider, Richard Griffiths, signaling confidence in the company's future.
• Significant investment of $2.7 million in open market purchases of ADSs.
• Richard Griffiths' aggregate beneficial ownership now stands at 24.4%, a substantial stake.

Future Outlook

NA

Management Comments

• Mr. Griffiths purchased an aggregate of 543,581 ADSs in open market transactions between May 8, 2025 and June 24, 2025 for an aggregate price of $2.7M.
• All purchases were for cash and were funded by companies or personal funds of Mr. Griffiths.
• Mr. Griffiths is a director and the controlling shareholder of each of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc and Cream Capital Limited and a controlling shareholder of Pinkey's Limited and possesses the power to direct the voting and disposition of these shares.

Industry Context

This filing reflects an individual's increased stake in a biotechnology company, which is a common occurrence in the financial markets. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• Richard Griffiths is the controlling shareholder and director of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc, and Cream Capital Limited, and a controlling shareholder of Pinkey's Limited.
• Shares are held by these entities, and Mr. Griffiths possesses the power to direct their voting and disposition.

Stakeholder Impact

• Shareholders: Increased insider ownership may be perceived as a positive signal, potentially boosting investor confidence.
• Management: The increased stake by a controlling shareholder could imply stronger oversight or alignment of interests.

Key Dates

Recommendation

Keywords

Silence Therapeutics, Richard Griffiths, Ora Capital Limited, Schedule 13D/A, Shareholder, Beneficial Ownership, ADSs, Open Market Purchase, Insider Buying, Equity, Investment, Biotechnology, Pharmaceuticals